Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus investigator's choice standard therapy in recurrent or metastatic head and neck squamous cell carcinoma
NL-OMON44471Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall survival. Started May 2015; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON44471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44471.